Tranexamic Acid as an Intervention in Placenta Previa
Interventional Drug in Placenta Previa
About this trial
This is an interventional treatment trial for Interventional Drug in Placenta Previa focused on measuring Placenta previa, Tranexamic acid, intervention, Double blind
Eligibility Criteria
Inclusion Criteria: Pregnant at 24 weeks gestation and more Vaginal bleeding due to placenta previa Stable hemodynamically Accept to participate in the trial Exclusion Criteria: Hypersensitivity to tranexamic acid Acquired defective color vision History of venous thromboembolism Pre-existing medical conditions (diabetes mellitus, hypertension, renal disease) Smokers Refused to participate in the trial
Sites / Locations
- Ariana kh. JawadRecruiting
- Kurdistan Board for Medical specialityRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Tranexamic acid group
Glucose water group
This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
Participants will receive 30 mL of 5% glucose water slowly intravenously immediately during the attack of the bleeding, twice daily for 48 hours. Accompanied with the usual expectant management care.